import type { DigestEntry } from './types';

// PCOS (Polycystic Ovary Syndrome) -- 11 entries, added 2026-08-08 as this
// app's eleventh real condition, and the FIRST genuinely non-autoimmune
// condition built out in this whole session -- every condition before it
// (Hashimoto's, RA, Psoriasis, Graves', T1D, Celiac, IBD, MS, Lupus,
// Sjögren's) is a real autoimmune disease; PCOS is a real endocrine and
// metabolic disorder instead, named directly in CLAUDE.md's own Beyond
// Hashimoto's research as one of the "9 non-autoimmune candidates" this
// app was always meant to reach eventually, not autoimmune scope creep.
//
// PCOS is built with the same reuse-first, self-advocacy-from-day-one
// discipline as every autoimmune condition before it, but its own real
// central mechanism, insulin resistance, is genuinely metabolic rather
// than immune, which gives this category real, direct overlap with this
// app's own Type 1 Diabetes research (the carbohydrate/fiber
// sub-criterion built for T1D is a real, honest reuse candidate here too)
// and with the My Meds work's own already-built inositol/potassium
// reference data.
//
// Every citation here was independently verified via WebSearch before
// being written in.
export const PCOS_ENTRIES: DigestEntry[] = [
  {
    id: 'pcos-overview',
    category: 'pcos',
    title: 'PCOS: A Common Hormone and Metabolism Disorder, Not an Autoimmune Disease',
    teaser: 'The most common hormonal condition in women of childbearing age, and a different kind of condition from every other one.',
    summary: "Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of childbearing age, affecting a substantial 8% to 13% of that population by the most widely used diagnostic standard. Diagnosis relies on the internationally used Rotterdam criteria: at least two of three features must be present, irregular or absent ovulation, clinical or lab-confirmed signs of excess androgens (male-pattern hormones), and polycystic ovarian appearance on ultrasound.\n\nUnlike every other condition built out so far, PCOS is not an autoimmune disease, the immune system isn't attacking the body's own tissue here, it's a hormone and metabolism disorder, with insulin resistance as its central, driving mechanism (covered directly in this category's next entry). PCOS looks different in different people: one person's most disruptive symptom (irregular periods, unwanted hair growth, acne, fertility difficulty, weight changes) can be mild or absent in someone else with the same diagnosis.",
    citations: [
      { source: 'Polycystic Ovary Syndrome, MedlinePlus, U.S. National Library of Medicine', url: 'https://medlineplus.gov/polycysticovarysyndrome.html' },
    ],
    overallTier: 'strong',
    relatedIds: ['migraine-menstrual-estrogen-withdrawal'],
  },
  {
    id: 'pcos-insulin-resistance-mechanism',
    category: 'pcos',
    title: 'Insulin Resistance Drives Most of PCOS at Once',
    teaser: "Not just a common complication of PCOS. A documented driver of the hormone imbalance itself, in a majority of patients.",
    summary:
      "Insulin resistance is the central mechanism connecting most of what PCOS actually does to the body, not a separate, unrelated complication that happens to show up alongside it. A direct case-control study found insulin resistance in 42.6% of PCOS patients versus 17.1% of matched controls, roughly two and a half times more common. The mechanism runs both directions: elevated insulin directly stimulates the ovaries' own hormone-producing cells to make more androgens, worsening the excess-hair-growth and acne symptoms PCOS is often first noticed for, while the resulting hyperandrogenism itself further disrupts normal ovulation.\n\nResearch also finds PCOS's insulin resistance mechanistically distinct from the more familiar insulin resistance of obesity or type 2 diabetes, affecting muscle tissue through a different signaling defect. This directly explains why the two most consistently evidence-backed levers covered elsewhere in this category, modest weight loss and myo-inositol supplementation, both work primarily by improving insulin sensitivity rather than targeting hormones directly.",
    citations: [
      { source: 'A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4417246/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-myo-dchiro-inositol', 'pcos-weight-loss-modest', 'type2-overview', 'type2-metabolic-syndrome-cluster', 'pcos-dairy-igf1-hyperandrogenism', 'prostate-metabolic-syndrome-bph-link', 'pcos-insulin-resistance-depression-mechanism'],
  },
  // Added 2026-08-24, fact-checking a shared Google AI Mode conversation on
  // diet and mental illness. This category's own sleep/mental-health entry
  // (pcos-sleep-mental-health-real-data) already covers anxiety comorbidity
  // broadly, this entry covers the specific insulin-resistance mechanism
  // proposed to drive it, distinct rather than duplicated, and matches the
  // same mechanism now documented for Type 2 Diabetes in that category's
  // own file.
  {
    id: 'pcos-insulin-resistance-depression-mechanism',
    category: 'pcos',
    title: "PCOS's Central Mechanism, Insulin Resistance, Is Independently Linked to Its Elevated Depression and Anxiety Risk",
    teaser: 'A pooled analysis found roughly a third of women with PCOS meet criteria for depression, and research finds the same insulin resistance driving PCOS\'s hormonal symptoms also disrupting the brain pathways that regulate mood.',
    summary:
      "PCOS carries a pooled depression prevalence of roughly 34.8%, with anxiety prevalence reported even higher depending on the screening tool used, both well above general-population rates. This category's insulin-resistance research above already established that mechanism as PCOS's central driver, hyperandrogenism, irregular cycles, and metabolic symptoms all trace back to it.\n\nResearch specifically into the mood connection finds the same neuroendocrine dysregulation, insulin resistance and elevated androgens together, plausibly disrupting the hypothalamic-pituitary-adrenal stress axis and neurotransmitter balance, a proposed mechanistic link independent of a person's weight or BMI. This doesn't reduce PCOS's mental health burden to a purely biochemical explanation, psychosocial factors (visible symptoms like hirsutism and acne, fertility concerns) matter too, but it means managing insulin resistance through diet and the other levers covered in this category carries a plausible mood benefit alongside its metabolic and reproductive ones.",
    citations: [
      { source: 'High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis, Human Reproduction', url: 'https://academic.oup.com/humrep/article/32/5/1075/3064352' },
      { source: 'Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes, PMC6382695', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382695/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['pcos-insulin-resistance-mechanism', 'pcos-sleep-mental-health-real-data', 'mentalhealth-glycemic-instability-mood', 'type2-insulin-resistance-depression-mechanism'],
  },
  {
    id: 'pcos-myo-dchiro-inositol',
    category: 'pcos',
    title: 'Myo-Inositol and D-Chiro-Inositol: A Well-Studied 40:1 Ratio, Already in The Reference Data',
    teaser: 'One of the better-evidenced supplements in the whole research base for any condition, at the exact ratio a trial found best.',
    summary: "Myo-inositol and D-chiro-inositol are two related compounds naturally present in the body, and PCOS supplementation research has converged on a specific, tested ratio between them. A direct comparison trial testing seven different myo-inositol-to-D-chiro-inositol ratios (56 PCOS patients, 3 months) found the 40:1 ratio worked best for restoring ovulation and normalizing hormone and metabolic measures, matching the natural physiological ratio the body itself maintains in blood plasma.\n\nThe distinct mechanism behind each half of the pair: myo-inositol increases how well cells take up glucose, while D-chiro-inositol increases how efficiently the body stores that glucose as glycogen, together reducing insulin resistance, the same mechanism this category's previous entry names as PCOS's central driver. Research finds this combination, at 4g myo-inositol plus 100mg D-chiro-inositol daily for 3 to 6 months, associated with improved insulin sensitivity, more regular ovulation, lower androgen levels, and better fertility outcomes, one of the better-evidenced supplements in the whole research base for any condition, at that same 40:1 ratio.",
    citations: [
      { source: 'The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios, PMID 31298405', url: 'https://pubmed.ncbi.nlm.nih.gov/31298405/' },
    ],
    overallTier: 'strong',
    relatedIds: ['chromium-insulin-sensitivity-honest'],
  },
  {
    id: 'pcos-spearmint-tea',
    category: 'pcos',
    title: 'Spearmint Tea: A Randomized Trial Found an Anti-Androgen Effect',
    teaser: 'A folk remedy with trial backing, and a reason visible hair-growth improvement takes longer than the hormone change itself.',
    summary:
      "Spearmint tea has a history as a folk remedy for excess hair growth in PCOS, and a randomized, placebo-controlled trial (42 women, 30 days, spearmint tea versus a placebo herbal tea, twice daily) found a measurable anti-androgen effect: free and total testosterone both dropped significantly in the spearmint group (testosterone reductions in the range of 20% to 30% compared to placebo), while the placebo group's hormone levels stayed essentially flat. The likely mechanism involves rosmarinic acid and flavonoid compounds in spearmint that appear to reduce circulating androgens.\n\nOne qualification: the same 30-day trial found no significant change yet in the actual, visible hirsutism score (a standardized measure of excess hair growth). That is a matter of timing rather than failure: hair follicles cycle slowly, so visible improvement in unwanted hair growth takes several months to show up even once the underlying hormone level has already changed. A low-risk, food-based option with trial support, best understood with a realistic timeline rather than expected to work overnight.",
    citations: [
      { source: 'Grant P, Phytotherapy Research, 2010, "Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial," PMID 19585478', url: 'https://pubmed.ncbi.nlm.nih.gov/19585478/' },
    ],
    overallTier: 'moderate',
  },
  {
    id: 'pcos-weight-loss-modest',
    category: 'pcos',
    title: 'Modest Weight Loss: A Specific, Quantified Threshold That Moves the Needle',
    teaser: "Not a demand for dramatic change. A recent trial found each single percentage point of weight lost measurably raised the odds of an outcome: ovulation actually returning.",
    summary:
      "Current PCOS treatment guidance recommends modest weight loss, just 5% to 10% of body weight, as an effective first step for those who are overweight, and the evidence behind that specific, modest target is stronger than the number might suggest.\n\nThe recent BAMBINI trial found ovulatory recovery at 52 weeks in 50.8% of participants overall, but the striking detail is the dose-response relationship within that: ovulatory recovery occurred in only 19% of participants who didn't lose weight, versus over 50% of those who did, and each single percentage point of body weight lost was associated with a measured 5.6% increase in the odds of ovulation actually returning. Broader research finds this same modest weight-loss range associated with improvement across PCOS's three main symptom domains at once, reproductive (ovulation, fertility), metabolic (insulin sensitivity), and psychological.",
    citations: [
      { source: 'Ovulatory Recovery following weight loss in women with polycystic ovary syndrome and obesity: a post hoc analysis of the BAMBINI randomised controlled trial, PMID 41808368', url: 'https://pubmed.ncbi.nlm.nih.gov/41808368/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-insulin-resistance-mechanism'],
  },
  {
    id: 'pcos-endometrial-cancer-risk',
    category: 'pcos',
    title: "An Elevated Cancer Risk Traced Directly Back to PCOS's Core Mechanism",
    teaser: 'Irregular ovulation isn\'t just a fertility inconvenience. Left unaddressed, it carries a measurable cancer risk.',
    summary:
      "PCOS carries a meaningfully elevated risk of endometrial cancer, roughly 2.7-fold higher in population studies (with some estimates ranging from 2 to 6 times higher), and the mechanism behind it traces directly back to PCOS's defining feature: anovulation. When ovulation doesn't happen regularly, the uterine lining (endometrium) is exposed to estrogen without the balancing effect progesterone normally provides after an ovulation cycle, a documented condition called unopposed estrogen exposure.\n\nResearch finds this estrogen-driven, unopposed proliferation can lead to endometrial hyperplasia (an overgrown lining) and, over enough uncorrected time, endometrial cancer itself. Standard surveillance for someone with prolonged irregular periods or abnormal bleeding includes transvaginal ultrasound and, when warranted, an endometrial biopsy. This is a direct, practical reason irregular or absent periods in PCOS deserve medical attention beyond fertility planning alone, not treated as a symptom to simply live with indefinitely.",
    citations: [
      { source: 'Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408229/' },
    ],
    overallTier: 'strong',
  },
  {
    id: 'pcos-hashimotos-comorbidity',
    category: 'pcos',
    title: "PCOS and Hashimoto's: A Bidirectional, Substantially Elevated Overlap",
    teaser: 'Each condition raises risk of the other, not just a one-way association, with numbers on both sides.',
    summary: "PCOS and Hashimoto's thyroiditis show a bidirectional overlap, each condition measurably raising the risk of the other, not simply co-occurring by chance. Population data finds the risk of PCOS increased 2.37-fold in people with Hashimoto's thyroiditis specifically, and separately, autoimmune thyroiditis and hypothyroidism run about three times more common in women with PCOS than in the general population. The overlap's strength varies meaningfully by population studied, data showing it running highest in Asian populations (4.56-fold), somewhat lower in European populations (3.27-fold), and lower still in South American populations (1.86-fold), a reason not to treat this as one fixed, universal number.\n\nA further practical finding: people with both conditions together show additionally elevated rates of diabetes (2.48-fold), high cholesterol (2.05-fold), and coronary artery disease (2.63-fold) compared to people with neither. For anyone managing either condition alone, a standard thyroid panel (covered in the Hashimoto's self-advocacy research) is a reasonable thing to ask about even without other thyroid symptoms yet, and the reverse holds too.",
    citations: [
      { source: 'Ho CH, et al., Annals of Translational Medicine, "Hashimoto\'s thyroiditis might increase polycystic ovary syndrome and associated comorbidities risks in Asia"', url: 'https://atm.amegroups.org/article/view/43229/html' },
      { source: 'Increased Risk of Polycystic Ovary Syndrome and Its Comorbidities in Women with Autoimmune Thyroid Disease', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177418/' },
    ],
    overallTier: 'strong',
    relatedIds: ['advocacy-core-thyroid-panel'],
  },
  {
    id: 'pcos-ogtt-screening',
    category: 'pcos',
    title: "Diabetes Screening in PCOS: Why a Simple Fasting Glucose Test Isn't Enough",
    teaser: 'The standard, simplest diabetes test misses more than half of cases in PCOS specifically. A more involved test is the actual recommendation.',
    summary:
      "Given how central insulin resistance is to PCOS (see this category's dedicated entry), standard diabetes screening deserves specific attention here rather than the general population's usual approach. An expert panel (the Androgen Excess Society) specifically recommends a 75-gram oral glucose tolerance test (OGTT), not a fasting glucose test alone, for exactly this reason: research found fasting glucose alone missed glucose intolerance in 58% of PCOS cases that an OGTT correctly caught.\n\nThe OGTT itself involves a standard process: a baseline blood draw, drinking a glucose solution, then a second blood draw two hours later, with a 2-hour value of 140 to 199 mg/dL indicating impaired glucose tolerance and 200 mg/dL or higher indicating diabetes itself. Guidance particularly recommends this for anyone with PCOS and a BMI over 30, a strong family history of type 2 diabetes, or age over 40, though the underlying research found fasting glucose inadequate regardless of age, weight, or androgen levels. Worth asking directly for the full OGTT rather than assuming a normal fasting glucose result is the complete picture.",
    citations: [
      { source: 'Diagnosis of disorders of glucose tolerance in women with polycystic ovary syndrome (PCOS) at a tertiary care center: fasting plasma glucose or oral glucose tolerance test?, PMID 30710572', url: 'https://pubmed.ncbi.nlm.nih.gov/30710572/' },
    ],
    overallTier: 'strong',
    relatedIds: ['type1-hba1c-time-in-range'],
  },
  {
    id: 'pcos-lipid-panel-cardiometabolic',
    category: 'pcos',
    title: "A Full Cardiometabolic Workup, Not Just a Reproductive-Health Checklist",
    teaser: "Up to 70% of PCOS patients carry insulin resistance. A complete lab panel exists specifically because of that number.",
    summary:
      "Clinical guidance recommends treating PCOS's workup as a full cardiometabolic evaluation, not only a reproductive-health checklist, given that up to 70% of women with PCOS carry insulin resistance.\n\nThe recommended panel includes fasting insulin, fasting glucose, HbA1c, and a full fasting lipid panel (total cholesterol, LDL, HDL, and triglycerides), alongside the OGTT covered in this category's dedicated entry. This panel is worth bringing to an appointment as a checklist, since PCOS is sometimes treated by a clinician as purely a fertility or menstrual-cycle issue, when the underlying metabolic picture deserves a separate, complete evaluation.",
    citations: [
      { source: 'Polycystic Ovarian Syndrome Workup, Medscape', url: 'https://emedicine.medscape.com/article/256806-workup' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-overview', 'cvd-lipid-panel-self-advocacy'],
  },
  {
    id: 'pcos-spironolactone-potassium',
    category: 'pcos',
    title: 'Spironolactone: A Medication for Androgen Symptoms, With a Potassium Caution',
    teaser: 'A common PCOS medication works by blocking a hormone that manages potassium. That mechanism carries a specific dietary caution.',
    summary:
      "Spironolactone is a commonly prescribed medication for PCOS's androgen-driven symptoms (excess hair growth, acne), working by blocking aldosterone, the hormone that normally regulates the body's sodium and potassium balance. That same mechanism carries a specific, practical caution: because spironolactone already reduces how much potassium the body clears, combining it with potassium-rich foods in large amounts, potassium supplements, or salt substitutes made from potassium chloride carries a risk of the blood potassium level climbing too high, a safety concern, not a minor question of nutrient timing.\n\nA separate and serious caution: spironolactone must be avoided entirely during pregnancy, since its anti-androgen effect carries a documented risk of feminizing a male fetus, which is exactly why it's typically paired with reliable contraception when prescribed for PCOS in someone who could become pregnant. Worth a direct conversation about both of these before starting, not assumptions either way.",
    citations: [
      { source: "Spironolactone's Role In Treating PCOS", url: 'https://healthmatch.io/pcos/spironolactone-for-pcos' },
    ],
    overallTier: 'strong',
    relatedIds: ['potassium-toxicity-hyperkalemia'],
  },
  {
    id: 'pcos-tying-together',
    category: 'pcos',
    title: 'What Actually Holds Up for PCOS, Pulled Together',
    teaser: "The first non-autoimmune condition, and one mechanism, insulin resistance, that explains almost everything else in this category at once.",
    summary: "Line up everything in this category and PCOS reads as a condition where one mechanism, insulin resistance, explains most of what else is happening, unlike the wider-ranging, multi-mechanism shape conditions like Lupus or Sjögren's showed. Myo-inositol's well-studied 40:1 ratio and modest, 5-10% weight loss both work primarily by improving that same insulin sensitivity, and both carry strong, specific trial evidence, myo-inositol among the better-evidenced supplements anywhere in the whole research base. Spearmint tea adds a separate, food-based lever specifically for androgen-driven symptoms, with a note about why visible results take longer than the hormone change itself.\n\nThe endometrial cancer risk and the bidirectional Hashimoto's overlap both argue for taking PCOS seriously as a systemic condition reaching well past fertility and appearance, the same argument Sjögren's lymphoma and kidney findings made for that condition. And the self-advocacy entries, the OGTT's superiority over fasting glucose alone, the full cardiometabolic panel, and spironolactone's potassium caution, all trace back to that same central insulin-resistance mechanism this whole category is built around.",
    citations: [
      { source: 'Polycystic Ovary Syndrome, MedlinePlus, U.S. National Library of Medicine', url: 'https://medlineplus.gov/polycysticovarysyndrome.html' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-insulin-resistance-mechanism', 'pcos-myo-dchiro-inositol', 'pcos-weight-loss-modest', 'pcos-hashimotos-comorbidity', 'pcos-endometrial-cancer-risk'],
  },

  // -- Full-depth parity additions, 2026-08-08. Every citation
  // independently verified via WebSearch.
  {
    id: 'pcos-rotterdam-phenotypes',
    category: 'pcos',
    title: "PCOS Isn't One Thing, Four Formally Named Phenotypes, With Different Risk Levels",
    teaser: "The Rotterdam criteria split PCOS into four phenotypes (A through D), and Phenotype A carries the highest metabolic and hormonal disruption while Phenotype D carries the lowest.",
    summary: "PCOS diagnosis runs on the Rotterdam criteria: two of three features (irregular or absent ovulation, biochemical or clinical hyperandrogenism, and polycystic-appearing ovaries on ultrasound) confirm the diagnosis, but WHICH two matters, splitting PCOS into four formally named phenotypes. Phenotype A (all three features present, the \"classic\" form) carries the most severe metabolic and hormonal disruption, the highest rates of insulin resistance and androgen excess. Phenotype B (hyperandrogenism plus anovulation, without the ovarian-appearance criterion) and Phenotype C (hyperandrogenism plus the ovarian finding, but with regular ovulation) fall in between.\n\nPhenotype D (anovulation plus the ovarian finding, but WITHOUT hyperandrogenism) carries the lowest metabolic risk of the four, meaning the practical focus for that phenotype specifically shifts toward the ovulation problem itself rather than the insulin-resistance-driven complications the PCOS research otherwise centers on. Not every PCOS diagnosis carries the same risk profile, and knowing which phenotype applies changes which parts of the PCOS research are most directly relevant.",
    citations: [
      { source: 'When one size does not fit all: Reconsidering PCOS etiology, diagnosis, clinical subgroups, and subgroup-specific treatments', url: 'https://www.sciencedirect.com/science/article/pii/S2666396124000037' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-insulin-resistance-mechanism'],
  },
  {
    id: 'pcos-sleep-mental-health-real-data',
    category: 'pcos',
    title: "PCOS's Reach Beyond Fertility: Sleep Apnea in Over a Third of Patients, and Anxiety in Over Three-Quarters",
    teaser: 'Pooled data finds obstructive sleep apnea in 37% of PCOS patients (versus 6% without PCOS), and a striking connected web linking sleep, mental health, and liver fat together.',
    summary: "PCOS's reach extends well past fertility and metabolic labs. Pooled data finds obstructive sleep apnea (OSA) in 37% of women with PCOS overall (29% in adolescents, 40% in adults), compared to just 6% in women without PCOS, a large gap that holds even after accounting for weight. Left untreated, that same OSA independently worsens insulin resistance and glucose intolerance, a direct feedback loop with PCOS's central mechanism.\n\nMental-health data is similarly striking: median depression prevalence of 36.6%, and anxiety reported in as high as 76.7% of PCOS patients in research, both independently tied to BMI and insulin resistance rather than existing in isolation. A third connected thread: PCOS carries a 2-4-fold higher NAFLD (fatty liver) risk independent of BMI, and OSA specifically predisposes toward it further, a three-way connected web (sleep, mood, liver) worth managing together rather than as separate, unrelated complaints.",
    citations: [
      { source: 'Obstructive sleep apnea syndrome in polycystic ovary syndrome: a systematic review and meta-analysis, PMC12006010', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12006010/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-insulin-resistance-mechanism'],
  },
  {
    id: 'pcos-history-milestones',
    category: 'pcos',
    title: "PCOS's History: Named for Two Doctors, Redefined Three Times Since",
    teaser: '1935, the 1990s, 2003, a seven-woman case series became a named syndrome, then needed formal reworking twice more as understanding of the condition grew.',
    summary: "PCOS's modern description dates to 1935, when Irving Stein and Michael Leventhal presented a case series of 7 women sharing menstrual irregularity, hirsutism, and infertility together, the first documented recognition that these features formed one connected condition rather than several unrelated complaints. For decades afterward, the condition carried their names, Stein-Leventhal Syndrome, and Stein's 1958 claim that surgery could cure it (a claim that hasn't held up against modern understanding of PCOS as a chronic, systemic condition).\n\nFormal diagnostic criteria didn't exist until an early-1990s NIH conference established the first agreed-upon definition; the Rotterdam criteria, covered in the phenotype research above, followed in 2003, expanding diagnosis to include ovarian ultrasound findings for the first time. Metformin's path to becoming a first-line PCOS treatment ran in parallel but separately: first synthesized in 1922, not approved for diabetes treatment (under the brand name Glucophage) until 1957, decades before its modern PCOS-specific use.",
    citations: [
      { source: 'The polycystic ovary syndrome: the first 150 years of study', url: 'https://www.sciencedirect.com/science/article/pii/S2666334122001398' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-rotterdam-phenotypes'],
  },
  {
    id: 'pcos-pregnancy-real-complications-letrozole',
    category: 'pcos',
    title: 'PCOS Pregnancy Carries Elevated Risk on Several Fronts, and a Newer Ovulation-Induction Drug That Outperforms the Older Standard',
    teaser: 'Elevated gestational diabetes and preeclampsia risk, both tracing back to the same insulin-resistance mechanism already central to this category, and letrozole, not clomiphene, is now the evidence-preferred first choice for inducing ovulation.',
    summary:
      "PCOS pregnancy carries elevated risk across several fronts, most tracing back to the same chronic inflammation, insulin resistance, and hyperandrogenism already central to this whole category: increased risk of implantation failure, early miscarriage, gestational diabetes, fetal growth restriction, preterm labor, and preeclampsia. The practical, actionable finding on how to actually get pregnant: letrozole, an aromatase inhibitor, has become the evidence-preferred first-line ovulation-induction drug for PCOS, outperforming the older standard, clomiphene, on higher ovulation and live-birth rates, a lower risk of multiple pregnancy, and a more favorable uterine-lining environment.\n\nLarge trial data found no increase in congenital anomalies, miscarriage, or adverse perinatal outcomes in letrozole-conceived pregnancies, and, notably, evidence that letrozole conception itself may REDUCE the incidence of gestational diabetes, hypertensive complications, and large-for-gestational-age infants compared to other conception routes, a reassuring finding for a medication choice that's already become the standard first option.",
    citations: [
      { source: 'Letrozole and clomiphene versus letrozole alone for ovulation induction in women with PCOS: a systematic review and meta-analysis, PMC12097446', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097446/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-insulin-resistance-mechanism'],
  },

  // -- Second depth pass, 2026-08-08, extending full-parity work to the
  // first 10 non-Hashimoto's conditions. Every citation independently
  // verified via WebSearch.
  {
    id: 'pcos-gut-microbiome-hyperandrogenism',
    category: 'pcos',
    title: 'Research Now Directly Links Reduced Gut Microbial Diversity to Higher Testosterone Levels in PCOS',
    teaser: 'A study of 73 PCOS patients found lower gut microbial diversity correlating directly with higher testosterone and hirsutism, and mouse studies show transplanting a PCOS gut microbiome alone can cause the same core disease features.',
    summary: "PCOS is tied to measurable gut microbiome changes that go beyond the insulin-resistance mechanism in the PCOS research. Research finds PCOS patients show a consistent pattern of gut dysbiosis, reduced overall microbial diversity, an altered ratio between two major bacterial groups (Firmicutes and Bacteroidetes), and abnormal metabolic byproducts.\n\nA study of 73 PCOS patients and 48 healthy controls found reduced gut microbial diversity correlating directly and negatively with hyperandrogenemia, total testosterone levels, and hirsutism (excess hair growth), a specific, quantified link between the gut and PCOS's hallmark hormonal symptoms. The proposed mechanisms include disrupted energy metabolism, altered lipid and bile acid processing, and chronic low-grade inflammation, mirroring the same gut-driven inflammatory pathway covered elsewhere for other autoimmune and metabolic conditions.\n\nStriking: animal research found that transplanting fecal microbiota from PCOS patients into healthy mice actually reproduced core PCOS features, including anovulation and metabolic dysfunction, evidence the gut microbiome isn't just a bystander marker but potentially a causal contributor. This connects PCOS's insulin-resistance mechanism to a second, gut-centered pathway, reinforcing why the whole-food, fiber-supportive dietary pattern already recommended elsewhere in the PCOS and gut-microbiome research applies here too.",
    citations: [
      { source: 'Gut Microbial Diversity in Women With Polycystic Ovary Syndrome Correlates With Hyperandrogenism, PMID 29370410', url: 'https://pubmed.ncbi.nlm.nih.gov/29370410/' },
      { source: 'Unraveling the gut microbiota\'s role in PCOS: a new frontier in metabolic health, PMC11958223', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11958223/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['pcos-insulin-resistance-mechanism'],
  },

  // -- Volumetric depth pass, 2026-08-08, continuing toward genuine
  // volumetric parity with Hashimoto's own depth, per direct instruction
  // that all 18 non-Hashimoto's conditions deserve the same fully
  // encompassing treatment, individually and in combination. Every
  // citation independently verified via WebSearch.
  {
    id: 'pcos-nafld-comorbidity',
    category: 'pcos',
    title: 'Fatty Liver Disease Affects Over Half of Women With PCOS, a Striking Comorbidity Driven by the Same Core Mechanism',
    teaser: 'Current worldwide data finds MASLD (fatty liver disease) in 51.56% of women with PCOS versus 29.64% of women without it, driven by the same insulin resistance and high androgen levels already central to PCOS itself.',
    summary: "PCOS carries a striking comorbidity with metabolic dysfunction-associated steatotic liver disease (MASLD, covered in depth in the dedicated fatty-liver-disease research), not two unrelated diagnoses. Current, racially and ethnically diverse worldwide data finds MASLD in 51.56% of women with PCOS compared to 29.64% of women without it, with a meta-analysis finding a pooled prevalence around 43% and a roughly 2.5-fold higher odds (odds ratio 2.54) of MASLD in PCOS. Important: research finds this connection independent of body weight, high androgen levels and insulin resistance, PCOS's core mechanisms, appear to drive liver injury directly, not merely through obesity as a middle step.\n\nResearch specifically finds women with PCOS who have hyperandrogenism (the classic phenotype) show a higher MASLD prevalence than PCOS without hyperandrogenism, even after accounting for other confounding factors. This is a concrete reason for anyone with PCOS to ask about liver health as part of routine screening, since the already-established MASLD research (weight-loss thresholds, exercise's independent benefit, the FIB-4 fibrosis-screening tool) applies directly and usefully to this common PCOS comorbidity, not just to fatty liver disease encountered on its own.",
    citations: [
      { source: 'Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome, Journal of Clinical Endocrinology & Metabolism', url: 'https://academic.oup.com/jcem/article/107/1/258/6365752' },
      { source: 'Non-Alcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression, PMC9917911', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917911/' },
    ],
    overallTier: 'strong',
    relatedIds: ['masld-overview', 'masld-fib4-fibrosis-screening'],
  },
  {
    id: 'pcos-combined-oral-contraceptives-first-line',
    category: 'pcos',
    title: 'Combined Oral Contraceptives Are the Formal First-Line Treatment for PCOS Itself, Not Just Birth Control',
    teaser: 'Current international guidelines name combined oral contraceptives the first-line treatment specifically for PCOS symptoms, with trial data finding cycle regularity improved from 0% to 100% versus no treatment.',
    summary: "Combined oral contraceptive pills (COCPs) are worth knowing directly as PCOS's formal, guideline-designated first-line pharmacologic treatment, not simply a birth control option that happens to also be used in PCOS. The current 2023 International Evidence-based Guideline for PCOS names combined oral contraceptives the first-line option specifically for managing irregular menstrual cycles and hirsutism (excess hair growth), the two hallmark symptoms covered elsewhere in the PCOS research.\n\nTrial data finds a striking effect on cycle regularity specifically, 100% regularity with COCP treatment versus 0% with no medical treatment at all, alongside improvements in quality of life and modest weight benefit. Research finds the certainty of evidence for benefits beyond cycle regulation, and for potential adverse effects, low, meaning COCPs' status as first-line treatment rests partly on their well-established general safety and efficacy record rather than PCOS-specific trial data at every level.\n\nOne specific caution: combined regimens containing an antiandrogen component may reduce hyperandrogenism somewhat more effectively, but research finds they carry a higher venous thrombotic event (blood clot) risk, so they aren't recommended as a first-line choice despite the theoretical androgen advantage. For anyone with PCOS being offered a birth control pill as treatment, this is the evidence-backed, guideline-recommended first-line therapy for the condition itself.",
    citations: [
      { source: 'Update to Guidelines for Treatment and Management of PCOS Using Combined Oral Contraceptive Pills, Endocrinology Advisor', url: 'https://www.endocrinologyadvisor.com/news/update-to-guidelines-for-treatment-and-management-of-pcos-using-combined-oral-contraceptive-pills/' },
      { source: 'Combined oral contraceptive pill compared with no medical treatment in the management of polycystic ovary syndrome: A systematic review, PMC10952804', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10952804/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-spironolactone-potassium', 'pcos-rotterdam-phenotypes'],
  },
  {
    id: 'pcos-ivf-real-outcomes',
    category: 'pcos',
    title: 'Fertility Data: Women With PCOS Actually Achieve Strong, Sometimes Better-Than-Average IVF Success Rates',
    teaser: 'A study of over 1,300 PCOS patients found a 63.48% cumulative live birth rate through IVF, and PCOS patients showed higher live birth rates than matched controls even after adjusting for age and weight.',
    summary: "PCOS is a common cause of infertility (covered through the letrozole-and-ovulation-induction research), but IVF outcome data offers a more hopeful picture than the diagnosis alone might suggest. A study of 1,380 PCOS patients found a conservative cumulative live birth rate of 63.48% through IVF, and a comparison of older PCOS patients (ages 35-46) against age- and weight-matched controls without PCOS found PCOS patients actually achieved a HIGHER cumulative live birth rate, 55.51% versus 38.02%, over two years of treatment.\n\nResearch finds this reflects a distinctive PCOS trait, better ovarian reserve and response to ovarian stimulation, which continues working in a woman's favor for IVF specifically even as PCOS's fertility challenges (irregular or absent ovulation) make natural conception harder. For those using the less invasive option first, intrauterine insemination (IUI), research finds a live birth rate of 17.80% per cycle and 30.95% cumulative per patient. This is encouraging data for early in a PCOS fertility conversation, rather than assuming PCOS automatically means a difficult or lower-probability path to a successful pregnancy: outcomes through assisted reproduction, particularly IVF, are often favorable.",
    citations: [
      { source: 'Comparison of Cumulative Live Birth Rate Between Aged PCOS Women and Controls in IVF/ICSI Cycles, PMC8505977', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505977/' },
      { source: 'Factors affecting cumulative live birth rate after the 1st oocyte retrieved in polycystic ovary syndrome patients in women during IVF/ICSI-ET, PMC10571446', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10571446/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-pregnancy-real-complications-letrozole'],
  },
  {
    id: 'pcos-dairy-igf1-hyperandrogenism',
    category: 'pcos',
    title: 'Why Dairy Specifically Gets Singled Out in PCOS: a Hormonal Pathway, Not Just a Diet Trend',
    teaser: "Milk raises insulin and IGF-1 in a way that's chemically similar to eating straight sugar, and IGF-1 directly drives the same androgen excess PCOS is built on.",
    summary:
      "PCOS already centers on insulin resistance as its dominant driver (see this category's overview), and dairy earns its specific reputation through that exact same pathway. Drinking milk produces a measurable rise in insulin and insulin-like growth factor 1 (IGF-1), comparable in size to the response from a high-glycemic meal.\n\nIGF-1 isn't a passive bystander here: it stimulates the enzyme that converts testosterone into its more potent form, activates androgen production in both the ovaries and adrenal glands, and amplifies how strongly cells respond to the androgens already circulating. That's the same hormonal cascade behind PCOS's acne, excess hair growth, and hair thinning.\n\nNot every dairy product behaves identically. Skim and whole milk both trigger a substantially stronger insulin/glycemic response than cheese does, likely because the liquid, rapidly-absorbed whey and casein proteins in milk itself are doing the work, rather than dairy fat or calcium generally. This doesn't mean dairy has to be eliminated outright. It means someone with PCOS whose skin or hair symptoms haven't responded to other changes has a mechanistic reason to specifically test whether milk itself, more than dairy as a whole, is a meaningful contributor.",
    citations: [
      {
        source: 'Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris, Experimental Dermatology 2009 (Melnik & Schmitz)',
        url: 'https://pubmed.ncbi.nlm.nih.gov/19709092/',
      },
    ],
    overallTier: 'moderate',
    relatedIds: ['pcos-insulin-resistance-mechanism', 'pcos-spearmint-tea'],
  },
  {
    id: 'pcos-glp1-agonists-emerging',
    category: 'pcos',
    title: 'GLP-1 Medications Are Moving Into PCOS Treatment, Working Through the Same Insulin Pathway This Condition Is Built On',
    teaser: "A randomized trial found combining semaglutide with metformin restored regular periods in 86.87% of women with PCOS, well above metformin alone.",
    summary: "GLP-1 receptor agonists (semaglutide, liraglutide, the same medication class covered in the Type 2 Diabetes and MASLD research) are increasingly being studied directly in PCOS, and the fit makes sense given this category's overview: PCOS runs largely on insulin resistance, and GLP-1 medications work by improving exactly that.\n\nA randomized trial of 64 women with PCOS and overweight or obesity compared metformin alone against metformin plus semaglutide over 12 weeks, and found the combination significantly reduced body weight, improved insulin resistance, lowered inflammatory markers, and restored regular menstrual cycles in 86.87% of participants, alongside a higher natural pregnancy rate.\n\nAn earlier, smaller trial comparing liraglutide directly against metformin found liraglutide produced greater weight loss and a more favorable reduction in visceral fat specifically. This is still-emerging evidence, mostly from smaller trials rather than the very large studies already available for GLP-1 use in general obesity or type 2 diabetes, and these medications aren't yet a standard, guideline-recommended first-line PCOS treatment the way combined oral contraceptives or metformin already are (see this category's research on both). It's worth-knowing context for a conversation with a doctor, especially for someone whose PCOS symptoms haven't responded well to standard first-line options.",
    citations: [
      { source: 'Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome, 2025', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12297736/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['pcos-weight-loss-modest', 'pcos-combined-oral-contraceptives-first-line', 'type2-glp1-sglt2-paradigm-shift'],
  },
  {
    id: 'pcos-amh-diagnostic-marker',
    category: 'pcos',
    title: 'A Blood Test Is Becoming Part of How PCOS Gets Diagnosed, Alongside the Existing Ultrasound',
    teaser: "Anti-Müllerian hormone (AMH) can't diagnose PCOS on its own, but a pooled analysis found it correctly identifies the condition about as often as the ultrasound-based test it's starting to supplement.",
    summary:
      "This category's research covers the Rotterdam criteria, the standard diagnostic framework requiring two of three features: irregular ovulation, clinical or lab evidence of excess androgens, and polycystic ovarian morphology on ultrasound. Anti-Müllerian hormone (AMH), a hormone produced by small ovarian follicles, is increasingly used as either a substitute or an added data point for that ultrasound criterion.\n\nA large, pooled meta-analysis (68 studies) found AMH had a sensitivity of 79% and specificity of 87% for diagnosing PCOS in adults, broadly comparable to how well the ultrasound-based criterion itself performs, with the practical advantage that a blood draw is more standardized and less operator-dependent than an ultrasound reading. The 2023 international evidence-based PCOS guideline now formally recommends AMH as an acceptable way to define polycystic ovarian morphology in adults.\n\nDirectly stated in the guideline itself: AMH alone still isn't adequate to diagnose PCOS on its own, and research finds it performs meaningfully less reliably in adolescents specifically, since normal, hormonally-active teenage ovaries can look similar to PCOS on this marker too. This is useful context for anyone navigating a PCOS diagnosis: one piece of the diagnostic picture rather than either a magic single test or a marker with no value.",
    citations: [
      { source: 'Anti-müllerian hormone as a diagnostic biomarker for polycystic ovary syndrome and polycystic ovarian morphology: a systematic review and meta-analysis, Fertility and Sterility 2024, PMID 38944177', url: 'https://pubmed.ncbi.nlm.nih.gov/38944177/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-rotterdam-phenotypes', 'pcos-ogtt-screening'],
  },
  {
    id: 'pcos-long-term-cardiovascular-risk',
    category: 'pcos',
    title: 'PCOS Carries a Substantially Elevated Long-Term Heart Attack and Stroke Risk, Not Just a Lipid-Panel Concern',
    teaser: 'A pooled meta-analysis of over 166,000 women found PCOS tracked with a 2.6-fold higher heart attack risk and nearly double the stroke risk, actual cardiovascular events, not just abnormal lab numbers.',
    summary:
      "The lipid-panel research names the measurable cardiometabolic lab abnormalities common in PCOS. A separate, larger body of evidence answers the harder, more consequential question directly: does PCOS actually translate into more heart attacks and strokes over time, not just worse numbers on paper.\n\nA pooled meta-analysis of 10 cohort studies and 166,682 women found PCOS tracked with a pooled 66% higher risk of cardiovascular events overall, a 2.57-times-higher heart attack risk, a 2.77-times-higher ischemic heart disease risk, and a nearly-doubled stroke risk, compared with women without PCOS.\n\nA separate UK Biobank cohort study found broadly consistent results (a 1.77-times-higher overall CVD risk, 2.27-times-higher coronary artery disease risk). The same meta-analysis found no significant difference in overall mortality or cardiovascular-specific death, a reassurance that this elevated event risk hasn't yet translated into a clearly higher death rate in the pooled data, though research elsewhere flags young, nonobese PCOS patients specifically as a group that may warrant earlier cardiovascular risk-management attention. This is substantial, long-term risk, a concrete reason the cardiometabolic monitoring this category's research already recommends matters well beyond fertility-focused care alone.",
    citations: [
      { source: 'Risk of Cardiovascular and Cerebrovascular Events in Polycystic Ovarian Syndrome Women: A Meta-Analysis of Cohort Studies, PMC7690560', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690560/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-lipid-panel-cardiometabolic', 'cvd-women-underdiagnosis-gender-gap'],
  },
  {
    id: 'pcos-vitamin-d-deficiency-real-data',
    category: 'pcos',
    title: 'A Striking Majority of Women With PCOS Run Vitamin D Deficient, Tracking With Worse Insulin Resistance',
    teaser: 'Research finds up to 85% of women with PCOS vitamin D deficient, roughly double the rate in the general population, and correlating directly with the insulin resistance already central to this condition.',
    summary: "Vitamin D deficiency shows up across the research on several conditions, and PCOS carries a particularly striking version of it. Research finds an estimated 67 to 85% of women with PCOS vitamin D deficient, compared with a 20 to 48% rate in the general adult population, a roughly-doubled gap.\n\nObservational research finds this isn't incidental: women with PCOS who are vitamin D deficient show worse markers of insulin resistance (higher fasting glucose, higher HOMA-IR scores) than those with adequate levels, and research finds an inverse relationship between vitamin D levels and both insulin resistance and BMI.\n\nMatching the same pattern already found for vitamin D across several other conditions: a meta-analysis of supplementation trials found vitamin D supplementation DID measurably reduce HOMA-IR scores compared with placebo, a positive intervention result, while a separate meta-analysis found no clear evidence it meaningfully improved PCOS's broader metabolic and hormonal picture overall. This striking deficiency rate makes vitamin D testing a worthwhile, low-cost addition to the cardiometabolic lab panel this category's research already recommends, with mixed evidence for whether correcting it meaningfully improves PCOS itself beyond the deficiency alone.",
    citations: [
      { source: 'Prevalence and influencing factors of vitamin D deficiency in women with polycystic ovary syndrome: a systematic review and meta-analysis, Frontiers in Nutrition 2026', url: 'https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2026.1865564/full' },
    ],
    overallTier: 'moderate',
    relatedIds: ['pcos-lipid-panel-cardiometabolic', 'vitamind-tying-together'],
  },
  {
    id: 'pcos-adolescent-diagnosis-challenge',
    category: 'pcos',
    title: "PCOS Is Hard to Diagnose in Teenagers, Because Normal Puberty Looks a Lot Like It",
    teaser: 'Research finds it is nearly impossible to distinguish PCOS-related irregular periods from the normal cycle irregularity of the first few years after a first period, so age-adjusted criteria exist specifically for teenagers.',
    summary:
      "Diagnosing PCOS in adolescents runs into a well-documented overlap problem: the same irregular periods that can signal PCOS are also completely normal in the first few years after menarche (a first period). Data finds roughly 75% of menstruating adolescents report cycles between 21 and 45 days in that first year, and most teens don't settle into a regular cycle until 2 to 3 years after their first period, with only 6.3% still having irregular cycles by the 3-year mark. Because of this overlap, medical guidelines use age-adjusted criteria rather than a single fixed rule: cycles under 21 or over 45 days count as irregular between 1 and 3 years post-menarche, tightening to under 21 or over 35 days after year 3, with true primary amenorrhea only flagged by age 15 or more than 3 years after breast development begins.\n\nIrregular cycles alone, especially in the first year after a first period, are considered a normal part of pubertal transition, not evidence of PCOS on their own, and guidance specifically advises against using pelvic ultrasound in this age group, since polycystic-looking ovaries are also a normal finding during typical puberty. A teenager with irregular periods alone very likely does not have PCOS, and a careful diagnosis in this age group depends on additional signs (persistent irregularity well past the expected window, or signs of excess androgen) rather than menstrual irregularity by itself.",
    citations: [
      { source: 'PCOS in Adolescents—Ongoing Riddles in Diagnosis and Treatment, PMC9918268', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9918268/' },
      { source: 'Adolescent polycystic ovary syndrome according to the international evidence-based guideline, PMC7092491', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092491/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-rotterdam-phenotypes', 'pcos-amh-diagnostic-marker'],
  },
  {
    id: 'pcos-global-south-asian-prevalence',
    category: 'pcos',
    title: 'PCOS in South Asian Women Runs More Common and More Metabolically Severe, a Documented Pattern',
    teaser: 'Women of South Asian ancestry (India, Pakistan, Bangladesh) show a higher PCOS prevalence, and data finds insulin resistance and metabolic syndrome showing up at a lower body weight than in other populations.',
    summary: "PCOS carries a well-documented ethnic pattern, relevant for anyone outside a purely Western context. Women from South Asian countries, India, Pakistan, and Bangladesh, show a higher PCOS prevalence than many other ethnic populations studied.\n\nThe more consequential difference is metabolic: South Asian women with PCOS carry an elevated risk of metabolic syndrome (central obesity, elevated fasting glucose, lower HDL cholesterol), with one study finding 37.5% metabolic syndrome prevalence in this specific population, and research finds insulin resistance and Type 2 diabetes risk showing up at lower body weight and waist circumference than in white European women with PCOS.\n\nResearchers describe this as the 'Asian Indian phenotype,' a documented pattern of greater visceral (internal, around-the-organs) fat accumulation and lower muscle mass at the same body weight, both of which independently drive higher insulin resistance. The PCOS/insulin-resistance research (the OGTT screening recommendation, the cardiometabolic lab panel) applies with extra urgency for anyone of South Asian ancestry specifically, since standard BMI-based screening thresholds built around a different reference population can under-catch metabolic risk in this group.",
    citations: [
      { source: 'Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS), Human Reproduction, Oxford Academic', url: 'https://academic.oup.com/humrep/article/26/1/202/708512' },
      { source: 'Prevalence and Predictors of Metabolic Syndrome in Women with Polycystic Ovarian Syndrome, PMC12784311', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12784311/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-overview', 'pcos-lipid-panel-cardiometabolic', 'pcos-ogtt-screening'],
  },
  {
    id: 'pcos-global-gulf-consanguinity',
    category: 'pcos',
    title: "PCOS in Gulf Arab States Runs Roughly Double the Global NIH-Criteria Rate, a Distinct Regional Pattern",
    teaser: "Pooled data finds PCOS diagnosed by NIH criteria at 18.8% in Gulf Arab states, more than double the 8.9% global pooled rate, tied to documented consanguinity and genetic patterns specific to the region.",
    summary: "The South Asian phenotype research is one regional pattern in PCOS; the Middle East and Gulf region shows a different one. A pooled analysis found PCOS prevalence by the strict NIH diagnostic criteria running at 18.8% specifically in Gulf Arab states, more than double the 8.9% global pooled rate under the same criteria, and among infertile women in Gulf Cooperation Council countries specifically, pooled PCOS prevalence reached a striking 30.0%.\n\nThe distinct contributing factor named directly in the research: consanguineous marriage (marriage between close relatives) remains common across much of the region, with documented rates exceeding 50% in countries including Saudi Arabia, Oman, and the UAE, and genome-wide research has found specific genetic variant combinations more common in women of Middle Eastern ancestry tied to more severe PCOS symptom presentation, particularly severe hirsutism and hyperandrogenism.\n\nOne complication layered on top: the region's diagnostic criteria haven't been standardized (studies use inconsistent follicle-count and hormone-testing thresholds), a methodological gap that likely affects how precisely these regional numbers can be compared to elsewhere. Elevated consanguinity specifically raises PCOS-relevant genetic risk in a documented, region-specific way the general PCOS research doesn't otherwise capture.",
    chart: {
      title: 'PCOS prevalence (NIH criteria): global vs. Gulf Arab states',
      unit: '%',
      data: [
        { label: 'Global pooled rate', value: 8.9 },
        { label: 'Gulf Arab states', value: 18.8 },
      ],
      sourceNote: 'Prevalence of polycystic ovary syndrome among infertile women in the Gulf Cooperation Council countries, ScienceDirect',
    },
    citations: [
      { source: 'Towards consensus: standardizing polycystic ovary syndrome (PCOS) diagnosis in the Middle East and North Africa (MENA) Region, Middle East Fertility Society Journal', url: 'https://link.springer.com/article/10.1186/s43043-025-00282-1' },
      { source: 'Prevalence of Common Gynecological Conditions in the Middle East: Systematic Review and Meta-Analysis, PMC9580651', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580651/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-global-south-asian-prevalence'],
  },
  {
    id: 'horizon-pcos',
    category: 'pcos',
    title: 'PCOS Treatment Is Moving Away From One-Size-Fits-All, Toward Drugs Aimed at Each Person\'s Driver',
    teaser: "The metformin and birth-control-pill research offers effective but general relief. Emerging drugs now target PCOS's specific, individual root causes directly, from a brain-signaling pathway to a plant-derived compound that blocks androgen production at its source.",
    summary:
      "The treatment research (combined oral contraceptives, metformin) offers broad symptom relief, but current research names it directly as failing to address PCOS's specific underlying drivers, which differ from person to person. The field is now actively developing mechanism-targeted alternatives across three categories: metabolic regulators (including the GLP-1 agonists, alongside newer approaches targeting a person's brown-fat activity), neuroendocrine modulators (NK3R antagonists, which directly calm the overactive brain signal, the GnRH pulse generator, driving excess androgen production in the first place), and androgen-synthesis inhibitors (including Artemisinin-derived compounds shown to block androgen production directly at its source).\n\nThe stated direction: using each person's genetic and hormonal profile to match them with the specific mechanism most likely to help, rather than the current practice of starting broad and adjusting from there. Most of this remains early-stage research, not yet available treatment, but it represents a shift in how the field is thinking about PCOS, as several distinct conditions sharing a name, not one uniform disease with one uniform treatment.",
    citations: [
      { source: 'Precision Targeted Therapy for PCOS: Emerging Drugs, Translational Challenges, and Future Opportunities', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12839070/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['pcos-combined-oral-contraceptives-first-line', 'pcos-insulin-resistance-mechanism'],
  },
  {
    id: 'horizon-pcos-fezolinetant',
    category: 'pcos',
    title: 'A Drug Cut PCOS-Driving Testosterone by 35% in 12 Weeks by Targeting the Brain, Not the Ovary',
    teaser: "The insulin-resistance mechanism explains most of PCOS's metabolic side. Fezolinetant instead targets an overactive brain signal directly, and a trial found it cutting testosterone, LH, and FSH all at once.",
    summary:
      "The precision-medicine research names neuroendocrine modulators as one emerging PCOS drug category, and fezolinetant is the most directly tested example. PCOS involves an overactive brain signal (an elevated GnRH pulse frequency) that drives excess luteinizing hormone and, downstream, excess androgen production, a different starting point from the insulin-resistance mechanism. Fezolinetant blocks a specific brain receptor (NK3R) that normally drives that overactive pulse.\n\nA Phase 2a trial found 12 weeks of fezolinetant reducing testosterone by roughly 35%, luteinizing hormone by about 60%, and follicle-stimulating hormone by about 18%, with the ratio between the two hormones (a useful PCOS marker) dropping by nearly 60% as well, substantial hormonal change from a drug that never touches the ovary directly. The same drug is already approved for a completely different use (menopausal hot flashes), meaning existing safety data already exists outside PCOS specifically. This represents a different treatment strategy, correcting the brain signal driving excess androgen production, rather than either directly blocking androgen's effects or improving insulin sensitivity the way this category's other treatments do.",
    citations: [
      { source: 'Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome, Journal of Clinical Endocrinology & Metabolism', url: 'https://academic.oup.com/jcem/article/106/9/e3519/6277155' },
    ],
    overallTier: 'strong',
    relatedIds: ['horizon-pcos'],
  },
  {
    id: 'pcos-hypertension-real-data',
    category: 'pcos',
    title: 'PCOS Carries a Quantified Hypertension Risk, Even in Young Women',
    teaser: 'A nationwide cohort study found young women with PCOS facing 62% higher hypertension risk than matched peers, and the risk shows up even in adolescent girls, well before midlife.',
    summary: "A large, nationwide population-based cohort study found young women with PCOS developing hypertension at a significantly higher rate than matched controls (7.85 versus 4.23 cases per 1,000 person-years, an adjusted hazard ratio of 1.62). A separate systematic review and meta-analysis found the same pattern across reproductive-age women broadly, a 1.70-fold increased relative risk.\n\nCross-sectional data adds a useful, specific number: 17.6 percent of women with PCOS have measurable hypertension, rising to 18.9 percent specifically in the \"classic\" PCOS phenotype (the form combining irregular periods, elevated androgens, and polycystic ovaries all at once) versus 12.9 percent in other phenotypes. This isn't just a midlife concern either, research in adolescent girls found hypertension-range blood pressure in 18.6 percent of those with PCOS versus 6.9 percent without, a meaningful gap showing up well before the age most people associate with blood-pressure risk.\n\nThe identified drivers (type 2 diabetes, obesity, family history, age 30 and up) are the same metabolic-syndrome cluster the PCOS research already centers on, a direct reason the insulin-resistance-focused management this category already recommends does double duty for blood pressure too, not a separate concern layered on top.",
    citations: [
      { source: 'Hypertension Risk in Young Women With Polycystic Ovary Syndrome: A Nationwide Population-Based Cohort Study, PMC7538684', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538684/' },
      { source: 'Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression, PMC7076940', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076940/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-overview', 'cvd-overview'],
  },
  {
    id: 'pcos-lean-phenotype-real-data',
    category: 'pcos',
    title: "'Lean PCOS' Undermines the 'PCOS Is a Weight Problem' Assumption",
    teaser: 'A meaningful share of PCOS patients are at a normal body weight, and research finds the same underlying insulin resistance driving the disease anyway.',
    summary:
      "The insulin-resistance mechanism is often assumed to be a weight-driven problem, but research directly confirms it isn't only that. Studies find insulin resistance in a striking 45 percent of lean PCOS patients (a normal body-mass index), compared with a higher but still-overlapping 75 to 95 percent range among overweight and obese PCOS patients. Direct comparison studies find that even at the same normal body weight, PCOS patients carry mild insulin resistance and abnormal lipid metabolism that non-PCOS women of the same weight don't have.\n\nAn additional finding: among lean PCOS patients specifically, research finds elevated LH (luteinizing hormone) and a higher LH-to-FSH ratio compared to obese PCOS patients, evidence that neuroendocrine (brain-hormone) disturbance, not fat tissue itself, may be the dominant driver in this specific subgroup. The practical takeaway: a normal-weight diagnosis of PCOS is not a sign the condition is somehow milder or less metabolically significant, it's evidence the disease's root mechanism can operate independently of body weight, since normal-weight patients are sometimes told their symptoms can't really be PCOS.",
    citations: [
      { source: 'Comparing Lean and Obese PCOS in Different PCOS Phenotypes, PMC9600591', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600591/' },
      { source: 'Insulin resistance and adverse metabolic profile in overweight/obese and normal weight of young women with polycystic ovary syndrome, PMC6121333', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121333/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-insulin-resistance-mechanism', 'pcos-weight-loss-modest'],
  },
  {
    id: 'pcos-eating-disorder-risk-real-data',
    category: 'pcos',
    title: 'PCOS Raises Eating-Disorder Risk, Regardless of Body Weight',
    teaser: 'A large 2024 meta-analysis found PCOS carries meaningfully higher odds of binge-eating disorder and bulimia nervosa, evidence now shaping official treatment guidelines.',
    summary:
      "Weight-loss guidance is a recurring theme across this category's research (covered by the modest-weight-loss and lifestyle entries), but a large 2024 systematic review and meta-analysis (28,922 women with PCOS and 258,619 controls, published in the Journal of Clinical Endocrinology and Metabolism) found something important alongside it: PCOS itself carries a significantly higher risk of eating disorders, specifically binge-eating disorder and bulimia nervosa, with the association growing even stronger (nearly three-fold higher odds) in studies using the formal Rotterdam diagnostic criteria.\n\nThis is direct evidence behind a practical clinical shift: the finding directly informed the 2023 international PCOS guideline update, which now explicitly recommends screening for disordered eating regardless of a patient's body weight, specifically when a doctor is giving lifestyle or dietary counseling. Repeated, well-meaning advice to restrict food or lose weight, without first checking for an eating disorder, carries a documented risk of doing harm in this specific population, not just being unhelpful.",
    citations: [
      { source: 'Increased Prevalence of Binge Eating Disorder and Bulimia Nervosa in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis, PMID 39115340', url: 'https://pubmed.ncbi.nlm.nih.gov/39115340/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-weight-loss-modest', 'pcos-sleep-mental-health-real-data', 'mentalhealth-ed-what-they-are'],
  },
  {
    id: 'pcos-hirsutism-quality-of-life-real-data',
    category: 'pcos',
    title: 'Of All PCOS Symptoms, Research Finds Hirsutism Carries the Single Biggest Hit to Quality of Life',
    teaser: "A direct comparison across the full range of PCOS symptoms found excess hair growth, not irregular periods or weight, the single strongest predictor of reduced quality of life.",
    summary:
      "The sleep and mental-health research already establishes a psychological burden in PCOS, and research finds one specific, visible symptom drives more of it than any other: hirsutism, excess coarse hair growth in a male-pattern distribution (face, chest, back), caused directly by the same androgen excess this category's insulin-resistance research covers.\n\nA study directly comparing the impact of different PCOS symptoms found hirsutism had the strongest association with reduced health-related quality of life, with the degree of hirsutism directly, proportionally tracking with how much quality of life dropped. A separate body of research finds hirsutism specifically, more than irregular periods, acne, or weight itself, independently associated with measurable anxiety and depression, consistent with the mental-health findings but pointing at one specific, visible symptom as a driver rather than PCOS as a diffuse whole.\n\nPractical evidence backs an intervention too: an observational study found laser hair-removal treatment for PCOS-related hirsutism producing a measurable, direct improvement in quality of life scores. Hirsutism is often treated as a cosmetic afterthought behind the 'more medically serious' concerns this category covers (insulin resistance, cardiovascular risk), but evidence finds it carries the single heaviest psychological weight of any PCOS symptom, worth taking seriously in its own right, not dismissed as vanity.",
    citations: [
      { source: 'Of PCOS Symptoms, Hirsutism Has the Most Significant Impact on the Quality of Life of Iranian Women, PMID 25874409', url: 'https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0123608' },
      { source: 'Understanding hirsutism in PCOS, PMID 38305206', url: 'https://pubmed.ncbi.nlm.nih.gov/38305206/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-sleep-mental-health-real-data', 'pcos-insulin-resistance-mechanism'],
  },
  {
    id: 'pcos-acanthosis-nigricans-visible-marker',
    category: 'pcos',
    title: 'Dark, Velvety Skin Patches Are a Visible, Often-Overlooked Sign of the Insulin Resistance Behind PCOS',
    teaser: "The insulin-resistance mechanism has a physically visible marker: acanthosis nigricans, dark, thickened, velvety skin, usually at the neck or underarms, affecting over half of PCOS patients in some studies.",
    summary:
      "The insulin-resistance research explains PCOS's central mechanism, and acanthosis nigricans, dark, thickened, velvety patches of skin typically appearing at the back of the neck, underarms, or skin folds, is a directly visible marker of that same underlying process, not a separate skin condition. Prevalence data finds it common in PCOS: one study found it in 53 percent of patients, significantly correlated with BMI, fasting insulin level, and HOMA-IR (a standard insulin-resistance marker), and a separate study in Pakistan found acanthosis present in 56.5 percent of PCOS cases, with a significant, direct association to insulin resistance itself.\n\nResearch in adolescents specifically finds the same pattern holding even before full PCOS diagnostic criteria are met, evidence it can serve as an early, visible clue worth raising with a doctor. Acanthosis nigricans isn't unique to PCOS (it shows up in obesity and prediabetes generally too), but its presence in someone already being evaluated for PCOS is meaningful, physical evidence pointing toward this category's central insulin-resistance mechanism, worth mentioning directly during an evaluation rather than dismissed as a cosmetic skin discoloration issue on its own.",
    citations: [
      { source: '[Acanthosis nigricans: metabolic interrelations inherent to the polycystic ovary syndrome], PMID 25272362', url: 'https://pubmed.ncbi.nlm.nih.gov/25272362/' },
      { source: 'Prevalence and clinical profile of insulin resistance in young women of polycystic ovary syndrome: A study from Pakistan, PMC3809275', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809275/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-insulin-resistance-mechanism', 'pcos-adolescent-diagnosis-challenge'],
  },
  {
    id: 'pcos-metformin-clomiphene-combination-real-data',
    category: 'pcos',
    title: "Metformin Alone Won't Reliably Cause Weight Loss in PCOS, but Added to Clomiphene, It Improves Ovulation Odds",
    teaser: "The GLP-1/metformin history entry names metformin's standard role, direct trial data finds it doesn't reliably drive weight loss on its own, yet improves ovulation success when combined with clomiphene.",
    summary:
      "The metformin-history and GLP-1-combination research names metformin as a standard PCOS treatment, and direct trial data draws two distinct lines. On weight loss specifically: while early, smaller studies suggested metformin alone might reduce weight, larger, more rigorous randomized controlled trials have failed to consistently confirm this, evidence that metformin isn't a reliable weight-loss drug on its own, consistent with structured, lifestyle-based weight loss remaining first-line for that specific goal.\n\nOn fertility and ovulation, the picture is more favorable: a direct trial found combining metformin with clomiphene citrate (a standard ovulation-induction medication) achieved significantly higher rates of regular cycles (71.4 versus 38.1 percent), successful ovulation (76.2 versus 38.1 percent), and actual conception (66.6 versus 28.6 percent) compared with clomiphene alone.\n\nA separate trial found even a short, 2-week course of metformin before starting clomiphene measurably reduced fasting insulin and insulin resistance and improved clomiphene's effectiveness. Metformin's best-evidenced role in PCOS fertility treatment is as a combination partner improving another drug's effectiveness, not as a standalone weight-loss solution, a useful distinction to keep in mind before expecting either outcome from it alone.",
    citations: [
      { source: 'Efficacy of combined metformin-clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome, PMC3725449', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725449/' },
      { source: 'Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome, PMID 16579997', url: 'https://pubmed.ncbi.nlm.nih.gov/16579997/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-glp1-agonists-emerging', 'pcos-weight-loss-modest'],
  },
  {
    id: 'pcos-endometrial-hyperplasia-screening-progestin',
    category: 'pcos',
    title: 'Endometrial Hyperplasia Affects Roughly a Third of PCOS Patients, and Simple Progestin Treatment Usually Resolves It',
    teaser: "The endometrial-cancer-risk entry names the mechanism, data finds the earlier, more common step, hyperplasia itself, affecting roughly 30% of PCOS patients, with effective progestin treatment available before cancer risk becomes the concern.",
    summary:
      "The endometrial-cancer entry names PCOS's 2.7-fold cancer risk and its direct mechanism (unopposed estrogen exposure from anovulation), and endometrial hyperplasia, the earlier, more common stage along that same pathway, deserves its direct, practical coverage. Research finds endometrial hyperplasia or carcinoma present in a substantial 30 percent of PCOS patients, with a separate meta-analysis finding premenopausal women with PCOS specifically facing up to a 4-fold increased endometrial cancer risk, a higher figure than the general 2.7-fold estimate.\n\nThe reassuring part: clinical guidance names conservative progestin therapy as the first-line treatment for non-atypical hyperplasia (the more common, less serious form), directly working by attenuating the same unopposed estrogen growth, the same protective mechanism combined oral contraceptives already provide preventively. This common intermediate step (hyperplasia, not yet cancer) is exactly why the ultrasound and biopsy surveillance matters as a practical screening tool, catching and treating a common, reversible condition with a simple hormonal treatment well before it could progress toward the more serious cancer risk this category's overview already names.",
    citations: [
      { source: 'TO BIOPSY OR NOT TO BIOPSY? PREVALENCE OF ENDOMETRIAL HYPERPLASIA AND CANCER IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME, Fertility and Sterility', url: 'https://www.fertstert.org/article/S0015-0282(22)00572-6/fulltext' },
      { source: 'Endometrial progesterone resistance and PCOS, PMC3917599', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917599/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-endometrial-cancer-risk', 'pcos-combined-oral-contraceptives-first-line'],
  },
  {
    id: 'pcos-bariatric-surgery-real-outcomes',
    category: 'pcos',
    title: 'Bariatric Surgery Helps PCOS, But Data Finds It Plateaus, and Doesn’t Fix Everything',
    teaser: "The weight-loss-threshold research covers modest, non-surgical loss, pooled surgical-outcome data finds bariatric surgery produces its distinct pattern of metabolic and reproductive improvement, with limits.",
    summary:
      "The weight-loss research (the BAMBINI trial) establishes a modest, non-surgical benefit threshold, bariatric surgery is a different, more intensive intervention, and pooled outcome data finds both benefit and limits. A 2024 systematic review and meta-analysis found women with PCOS experience metabolic and hormonal improvements after bariatric surgery comparable to women without PCOS, with a specific pattern: most metabolic parameters improved significantly by 3 months after surgery, then plateaued, with only triglycerides and HDL cholesterol continuing to improve beyond that point.\n\nOn the reproductive side, a sustained improvement in ovulatory dysfunction was found, tracking with a reduction in luteinizing hormone. The limitation: testosterone levels and polycystic ovarian appearance on ultrasound showed only limited improvement after surgery, and anti-Müllerian hormone (AMH, covered elsewhere in this category as a diagnostic marker) didn't meaningfully change at all, direct evidence that surgical weight loss, however dramatic, doesn't fully reverse every one of PCOS's underlying hormonal features.\n\nThe review's authors also named an important caveat about the whole evidence base: existing research is limited and of relatively low quality, especially for reproductive outcomes like actual pregnancy rates, not yet as well studied as the metabolic outcomes. This is benefit for a more intensive intervention, reported alongside its limits, not oversold as a complete fix for every part of the condition.",
    citations: [
      { source: 'Impact of bariatric surgery on anthropometric, metabolic, and reproductive outcomes in polycystic ovary syndrome: a systematic review and meta-analysis, Obesity Reviews', url: 'https://onlinelibrary.wiley.com/doi/10.1111/obr.13737' },
      { source: 'Bariatric Surgery Impact on Women with Polycystic Ovary Syndrome: A Prospective Cohort Study, PMID 40207015', url: 'https://pubmed.ncbi.nlm.nih.gov/40207015/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-weight-loss-modest', 'pcos-lean-phenotype-real-data'],
  },
  {
    id: 'pcos-diagnostic-delay-real-patient-experience-data',
    category: 'pcos',
    title: 'A Large Survey Found a Third of Women Wait Over 2 Years and See 3+ Doctors Before an Actual PCOS Diagnosis',
    teaser: "The adolescent-diagnosis-challenge entry names an early-life diagnostic difficulty, direct survey data of 1,385 women finds the delay extends well past adolescence, with measured consequences for how satisfied patients feel about their diagnosis experience.",
    summary:
      "The adolescent-diagnosis-challenge research names early-life diagnostic difficulty, and a large, direct patient-experience survey finds this delay is a common, adult problem too, not just a pediatric one. A survey of 1,385 women with a reported PCOS diagnosis found more than a third (33.6 percent) waited over 2 years from first raising symptoms to actually receiving a diagnosis, and nearly half (47.1 percent) saw 3 or more different health professionals before getting one. A separate survey of 323 women found a somewhat shorter median delay of 6 to 12 months, useful evidence the exact delay varies across different study populations, but the broader pattern (a meaningful subset facing years-long delays and multiple providers) held consistently across both.\n\nThe direct, measured consequence: the same research found longer diagnostic timelines and seeing more providers were independently associated with lower patient satisfaction with the whole diagnosis experience, alongside documented mental-health impact from prolonged symptom uncertainty. This common delay is direct evidence the complications (metabolic, cardiovascular, fertility-related) can go unaddressed for years while a diagnosis remains unconfirmed, a practical reason to push for the specific, diagnostic workup this category's overview already names (the Rotterdam criteria, an OGTT, a lipid panel) directly and proactively, rather than waiting for a diagnosis to be volunteered.",
    citations: [
      { source: 'Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome, PMID 27906550', url: 'https://pubmed.ncbi.nlm.nih.gov/27906550/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-adolescent-diagnosis-challenge', 'pcos-rotterdam-phenotypes'],
  },
  {
    id: 'pcos-mediterranean-lowcarb-real-trial',
    category: 'pcos',
    title: 'How Diet Affects PCOS: A 72-Patient Trial Found a Combined Mediterranean/Low-Carb Pattern Outperforms Low-Fat',
    teaser: "The dairy, inositol, and spearmint-tea findings each cover one specific piece, a randomized trial testing a full dietary pattern found it directly outperforming a standard low-fat diet across weight, hormones, and insulin.",
    summary:
      "The dairy-IGF1, myo-inositol, and spearmint-tea research each addresses one specific piece of PCOS's dietary picture, and a randomized controlled trial directly answers the broader question of whole dietary pattern. The trial randomized 72 overweight PCOS patients to 12 weeks of either a combined Mediterranean/low-carbohydrate diet or a standard low-fat diet.\n\nMeasured results favored the Mediterranean/low-carb group across every category tracked: weight loss (6.10kg versus 4.79kg), waist circumference (a 6.12cm reduction versus 3.90cm), and body fat percentage (2.97 percent versus 1.19 percent). The hormonal results matter most directly for PCOS's core mechanism,: total testosterone dropped in the Mediterranean/low-carb group while it actually rose slightly in the low-fat group, and LH (covered in this category's lean-phenotype research) fell more sharply too.\n\nMetabolic markers moved the same direction: fasting insulin dropped nearly twice as much (4.88 versus 8.53 uU/mL) in the Mediterranean/low-carb group, direct evidence reaching the central insulin-resistance mechanism, not just weight or cosmetic symptoms. This is randomized, controlled trial evidence, not just observation, that the SPECIFIC combination of a Mediterranean eating pattern with reduced carbohydrate intake, rather than either low-fat dieting or lower-carb eating alone, produces better hormonal and metabolic results for PCOS specifically.",
    citations: [
      { source: 'Mediterranean Diet Combined With a Low-Carbohydrate Dietary Pattern in the Treatment of Overweight Polycystic Ovary Syndrome Patients, PMID 35445067', url: 'https://pubmed.ncbi.nlm.nih.gov/35445067/' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-dairy-igf1-hyperandrogenism', 'pcos-insulin-resistance-mechanism', 'pcos-lean-phenotype-real-data'],
  },
  {
    id: 'pcos-fermented-drinks',
    category: 'pcos',
    title: 'Fermented Drinks and Foods for PCOS',
    teaser: 'The same low-residual-sugar principle that matters for blood sugar in Type 2 Diabetes matters here too once a fermentation has fully finished, PCOS is centrally an insulin-resistance condition even without a diabetes diagnosis attached.',
    summary: "This app's Water Kefir and Beet Kvass carry the lowest residual sugar once fully fermented, a better choice than Amazake or Sobia, both meaningfully sweeter drinks even at their most fermented.\n\nThe Wild-Fermented Red Grape, Ginger & Turmeric Tonic carries resveratrol, an antioxidant with early, mostly animal-study evidence for supporting Akkermansia muciniphila, a gut bacterium linked to healthy insulin signaling, an interesting thread given PCOS's central insulin-resistance mechanism, but still early evidence, not something to expect a measurable result from. The already-established caution against dairy's IGF-1 content applies to this app's dairy-based drinks (Milk Kefir, Ayran, Mango Lassi, Tarag-Style) the same way it does to dairy generally.",
    citations: [
      { source: 'Resveratrol as a promising nutraceutical: gut microbiota modulation review, MDPI', url: 'https://www.mdpi.com/1422-0067/25/6/3370' },
    ],
    overallTier: 'weak',
    relatedIds: ['recipe-ferment-water-kefir', 'recipe-ferment-beet-kvass', 'recipe-ferment-tonic-red-grape-ginger-turmeric', 'pcos-dairy-igf1-hyperandrogenism'],
  },
  // 2026-08-21, added after fact-checking NOVA's "The Truth About Fat"
  // (2020) documentary against the peer-reviewed literature, direct
  // request. The documentary itself is not treated as a citable source;
  // this traces to the primary study, independently verified via
  // WebSearch.
  {
    id: 'pcos-adiponectin-leptin-imbalance',
    category: 'pcos',
    title: 'PCOS Carries a Documented Adipokine Imbalance: High Leptin, Low Adiponectin',
    teaser: 'PCOS cases are over three times more likely to have low adiponectin than matched controls, independent of insulin resistance, a distinct hormonal signature on top of the insulin-resistance story.',
    summary: "The Health Literacy hormones research covers leptin and adiponectin as two fat-derived hormones that normally run in opposite directions from each other. PCOS shows a documented, specific version of that imbalance: leptin runs measurably higher and adiponectin measurably lower than in matched controls, and PCOS cases were found to be 3.2 times more likely to have low adiponectin even after adjusting for age, BMI, and insulin resistance, meaning the adiponectin drop isn't just a side effect of carrying more weight.\n\nAdiponectin also directly suppresses androgen production in ovarian theca cells in laboratory studies, giving this a plausible direct link to PCOS's hyperandrogenism, not just an incidental correlation. Worth reading alongside the existing insulin-resistance research rather than instead of it: this is a second, adipokine-specific piece of the same hormonal picture.",
    citations: [
      { source: 'Association between circulating adiponectin levels and polycystic ovarian syndrome (PMID 24502610)', url: 'https://pubmed.ncbi.nlm.nih.gov/24502610/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['pcos-insulin-resistance-mechanism', 'adiponectin-overview', 'leptin-reproductive-axis'],
  },
  {
    id: 'pcos-time-restricted-eating-trial',
    category: 'pcos',
    title: 'A 6-Month Trial Found Time-Restricted Eating Lowered Androgens in PCOS, Not Just Weight',
    teaser: 'Both time-restricted eating and calorie restriction improved insulin resistance in this trial, but only time-restricted eating also lowered a marker of excess androgen.',
    summary: "A 6-month randomized trial in 76 women with PCOS compared time-restricted eating (all food between 1pm and 7pm, no calorie counting), calorie restriction, and a control group. Insulin resistance, measured by HOMA-IR, decreased in both the time-restricted and calorie-restricted groups relative to control, and body weight dropped by about 4 to 5% in both groups too, so on those two measures the two approaches performed about the same.\n\nThe free androgen index, a marker of the excess androgen production central to PCOS, decreased in the time-restricted group specifically, not in the calorie-restriction group, suggesting a hormonal benefit from meal timing itself, separate from weight loss. This is a new and still-thin evidence base: an earlier systematic review found only one prior controlled trial in this population at all, so this single trial, however encouraging, needs replication before time-restricted eating should be treated as an established PCOS management tool rather than a promising early finding.",
    citations: [
      { source: 'Time-restricted eating plus calorie-restricted diet versus calorie-restricted diet in women with polycystic ovary syndrome', url: 'https://www.sciencedirect.com/science/article/pii/S2589004225019157' },
      { source: 'The Effect of Time-Restricted Eating on Insulin Levels and Insulin Sensitivity in Patients with Polycystic Ovarian Syndrome: A Systematic Review', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507776/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['chrono-early-time-restricted-eating', 'chrono-time-restricted-eating-nuance', 'pcos-insulin-resistance-mechanism'],
  },

  // Complementary & Manual Therapies, added 2026-09-04. The largest and
  // best-powered trial anywhere in this batch, and it is negative. That
  // is precisely why it leads: a 1,000-woman properly controlled null
  // result is more informative than a dozen small positive ones.
  {
    id: 'complementary-pcos-acupuncture-live-birth',
    category: 'pcos',
    title: 'A Thousand Women, Four Groups, and Acupuncture Made No Difference to Live Births',
    teaser:
      'The largest trial of acupuncture in PCOS was designed to detect a benefit on live birth. Active acupuncture did no better than sham, and the drug did all the work.',
    summary:
      "Acupuncture is widely offered for PCOS-related infertility, and it has been tested about as rigorously as anything in this field. A trial published in JAMA in 2017 randomized 1,000 women with PCOS across 27 hospitals in mainland China in a factorial design: active or control acupuncture, twice weekly, crossed with clomiphene or placebo for up to four cycles. Active acupuncture used deep needling with manual and electrical stimulation; control acupuncture used superficial insertion, no manual stimulation, and mock electricity.\n\nThe primary outcome was live birth, which is the outcome that actually matters rather than a hormone level or an ovulation count. Live births occurred in 29.4% with active acupuncture plus clomiphene, 28.0% with control acupuncture plus clomiphene, 13.9% with active acupuncture plus placebo, and 16.8% with control acupuncture plus placebo. Reading down that list shows the shape clearly. Clomiphene roughly doubled live births.\n\nAcupuncture changed nothing, in either the presence or the absence of the drug, and in the placebo arms the sham group did slightly better than the active one. Over 92% of participants completed the trial, so the null is not an artifact of dropouts. This is a well-powered, properly controlled negative result, worth more than a shelf of small positive studies. Someone offered acupuncture for PCOS fertility is entitled to know it has been tested at this scale and did not work.",
    citations: [
      {
        source:
          'Wu XK, Stener-Victorin E, Kuang HY, et al. 2017: Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial (JAMA 317(24):2502-2514)',
        url: 'https://pubmed.ncbi.nlm.nih.gov/28655015/',
      },
    ],
    overallTier: 'strong',
    relatedIds: [
      'handson-acupuncture-where-it-does-nothing',
      'handson-acupuncture-chronic-pain',
      'handson-tracking-whether-it-works',
      'pcos-insulin-resistance-mechanism',
    ],
  },
];
